[go: up one dir, main page]

ES2163410T3 - Derivados de benzodiazepina. - Google Patents

Derivados de benzodiazepina.

Info

Publication number
ES2163410T3
ES2163410T3 ES93917939T ES93917939T ES2163410T3 ES 2163410 T3 ES2163410 T3 ES 2163410T3 ES 93917939 T ES93917939 T ES 93917939T ES 93917939 T ES93917939 T ES 93917939T ES 2163410 T3 ES2163410 T3 ES 2163410T3
Authority
ES
Spain
Prior art keywords
rent
optionally replaced
azaciclic
azabiciclic
nr6r7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917939T
Other languages
English (en)
Inventor
Pineiro Jose Luis Castro
William Robert Carling
Mark Stuart Chambers
Stephen Robert Fletcher
Sarah Christine Hobbs
Victor Giulio Matassa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929216123A external-priority patent/GB9216123D0/en
Priority claimed from GB929216238A external-priority patent/GB9216238D0/en
Priority claimed from GB929216231A external-priority patent/GB9216231D0/en
Priority claimed from GB929220957A external-priority patent/GB9220957D0/en
Priority claimed from GB929222821A external-priority patent/GB9222821D0/en
Priority claimed from GB929222934A external-priority patent/GB9222934D0/en
Priority claimed from GB929223583A external-priority patent/GB9223583D0/en
Priority claimed from GB929226242A external-priority patent/GB9226242D0/en
Priority claimed from GB929226360A external-priority patent/GB9226360D0/en
Priority claimed from GB939301277A external-priority patent/GB9301277D0/en
Priority claimed from GB939307318A external-priority patent/GB9307318D0/en
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of ES2163410T3 publication Critical patent/ES2163410T3/es
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • C07D221/24Camphidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Absorbent Articles And Supports Therefor (AREA)

Abstract

LOS COMPUESTOS DE LA FORMULA (I), Y LAS SALES Y PROFARMACOS DE LOS MISMOS, EN DONDE R1 REPRESENTA H, ALQUILO C1-6 OPCIONALMENTE SUSTITUIDO O CICLOALQUILO C3-7; R2 ES NHR12 O (CH2)SR13 DONDE S ES 0, 1 O 2; R3 REPRESENTA ALQUILO C1-6, HALO O NR6R7; R4 Y R5 SON H, ALQUILO C1-12 OPCIONALMENTE SUSTITUIDO POR NR9R9'' O UN GRUPO AZACICLICO O AZABICICLICO, CICLOALQUILO R4-9 OPCIONALMENTE SUSTITUIDO, CICLOALQUILC4-9ALQUILOC1-4, ARILO, ARILALQUILO C1-6 O GRUPOS AZACICLICOS O AZABICICLICOS, O R4 Y R5 JUNTOS FORMAN EL RESIDUO DE UN SISTEMA EN ANILLO AZACICLICO O AZABICICLICO OPCIONALMENTE SUSTITUIDO; X ES 0, 1, 2 O 3; R12 ES FENILO OPCIONALMENTE SUSTITUIDO O PIRIDILO; R13 REPRESENTA UN GRUPO (A) EN DONDE R14 ES H O ALQUILO C1-6; R15 ES H, ALQUILO C1-6, HALO O NR6R7; Y LA LINEA DE PUNTOS ES UN ENLACE COVALENTE OPCIONAL; SON ANTAGONISTAS DE CCK Y/O DE LA GASTRINA UTILES EN TERAPIAS.
ES93917939T 1992-07-29 1993-07-28 Derivados de benzodiazepina. Expired - Lifetime ES2163410T3 (es)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GB929216123A GB9216123D0 (en) 1992-07-29 1992-07-29 Therapeutic agents
GB929216231A GB9216231D0 (en) 1992-07-30 1992-07-30 Therapeutic agents
GB929216238A GB9216238D0 (en) 1992-07-30 1992-07-30 Therapeutic agents
GB929220957A GB9220957D0 (en) 1992-10-06 1992-10-06 Therapeutic agents
GB929222821A GB9222821D0 (en) 1992-10-30 1992-10-30 Therapeutic agents
GB929222934A GB9222934D0 (en) 1992-11-02 1992-11-02 Therapeutic compounds
GB929223583A GB9223583D0 (en) 1992-11-11 1992-11-11 Therapeutic agents
GB929226242A GB9226242D0 (en) 1992-12-16 1992-12-16 Therapeutic agents
GB929226360A GB9226360D0 (en) 1992-12-17 1992-12-17 Therapeutic agents
GB939301277A GB9301277D0 (en) 1993-01-22 1993-01-22 Therapeutic agents
GB939307318A GB9307318D0 (en) 1993-04-07 1993-04-07 Therapeutic agents
PCT/GB1993/001599 WO1994003437A1 (en) 1992-07-29 1993-07-28 Benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
ES2163410T3 true ES2163410T3 (es) 2002-02-01

Family

ID=27581673

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917939T Expired - Lifetime ES2163410T3 (es) 1992-07-29 1993-07-28 Derivados de benzodiazepina.

Country Status (13)

Country Link
US (1) US5618812A (es)
EP (1) EP0652871B1 (es)
JP (1) JP3457312B2 (es)
AT (1) ATE207064T1 (es)
AU (1) AU671477B2 (es)
CA (1) CA2140009A1 (es)
DE (1) DE69330959T2 (es)
DK (1) DK0652871T3 (es)
ES (1) ES2163410T3 (es)
GR (1) GR3036924T3 (es)
LV (1) LV12956B (es)
PT (1) PT652871E (es)
WO (1) WO1994003437A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003447A1 (en) * 1992-07-29 1994-02-17 Merck Sharp & Dohme Limited Benzodiazepine derivatives
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
KR100561963B1 (ko) * 1995-12-11 2006-11-30 뉴 잉글랜드 메디컬 센터 호스피털스 인코퍼레이티드 펩타이드호르몬수용체리간드의검사방법및용도
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5852010A (en) * 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5929071A (en) * 1996-07-02 1999-07-27 Merck & Co., Inc. Method for the treatment of preterm labor
AU3591697A (en) * 1996-07-02 1998-01-21 Merck & Co., Inc. Method for the treatment of preterm labor
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
AU778005B2 (en) 1998-12-24 2004-11-11 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of Abeta protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
WO2001027091A1 (en) 1999-10-08 2001-04-19 Du Pont Pharmaceuticals Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
CZ20021663A3 (cs) 1999-10-15 2002-09-11 F. Hoffmann-La Roche Ag Nové deriváty benzodiazepinu
CA2395862A1 (en) 2000-02-17 2001-08-23 Hong Liu Succinoylamino carbocycles and heterocycles as inhibitors of a.beta. protein production
MXPA02009755A (es) 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de proteina a-beta.
CN1434803A (zh) 2000-04-03 2003-08-06 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白质产生抑制剂的环内酰胺
US20100009966A1 (en) * 2001-04-11 2010-01-14 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of abeta protein production
US6632812B2 (en) 2000-04-11 2003-10-14 Dupont Pharmaceuticals Company Substituted lactams as inhibitors of Aβ protein production
US6878363B2 (en) * 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
AU783857B2 (en) 2000-06-01 2005-12-15 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a beta protein production
US6977241B2 (en) * 2000-08-22 2005-12-20 The United States Of America As Represented By The Department Of Health & Human Services SH2 domain binding inhibitors
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
US6974869B2 (en) * 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
DE10163595A1 (de) * 2001-12-21 2003-08-07 Gruenenthal Gmbh In 3-Position heterocyclisch substituierte Piperidin-2,6-dione
US7845356B2 (en) * 2002-09-06 2010-12-07 Koninklijke Philips Electronics N.V. Implantable devices, systems, and methods for maintaining desired orientations in targeted tissue regions
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
US7781503B2 (en) * 2005-12-29 2010-08-24 Firestone Polymers, Llc Modified asphalt binders and asphalt paving compositions
US7642302B2 (en) 2005-12-29 2010-01-05 Firestone Polymers, Llc Modified asphalt binders and asphalt paving compositions
WO2008128889A1 (en) 2007-04-19 2008-10-30 F. Hoffmann-La Roche Ag Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
EP2146722A4 (en) * 2007-05-10 2011-08-03 Amr Technology Inc ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND THEIR USE FOR BLOCKING THE RECOVERY OF NOREPINEPHRIN, DOPAMINE AND SEROTONINE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96613A0 (en) * 1989-12-18 1991-09-16 Merck & Co Inc Pharmaceutical compositions containing benzodiazepine analogs
CA2032226A1 (en) * 1989-12-18 1991-06-19 Mark G. Bock Benzodiazepine analogs
EP0609306A1 (en) * 1991-10-24 1994-08-10 MERCK SHARP & DOHME LTD. Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors
CA2083891A1 (en) * 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
WO1993012791A1 (en) * 1991-12-20 1993-07-08 Merck Sharp & Dohme Limited Central cholecystokinin antagonists having pharmaceutical activity
GB9209518D0 (en) * 1992-05-01 1992-06-17 Merck Sharp & Dohme Therapeutic agents
US5360802A (en) * 1992-05-11 1994-11-01 Merck Sharpe & Dohme Ltd. Benzodiazepine derivatives, compositions containing them and their use in therapy
WO1994003447A1 (en) * 1992-07-29 1994-02-17 Merck Sharp & Dohme Limited Benzodiazepine derivatives

Also Published As

Publication number Publication date
LV12956B (en) 2003-06-20
DE69330959D1 (de) 2001-11-22
JPH07509482A (ja) 1995-10-19
EP0652871B1 (en) 2001-10-17
EP0652871A1 (en) 1995-05-17
AU671477B2 (en) 1996-08-29
ATE207064T1 (de) 2001-11-15
DK0652871T3 (da) 2001-12-03
WO1994003437A1 (en) 1994-02-17
GR3036924T3 (en) 2002-01-31
US5618812A (en) 1997-04-08
DE69330959T2 (de) 2002-04-11
AU4717893A (en) 1994-03-03
CA2140009A1 (en) 1994-02-17
PT652871E (pt) 2002-03-28
JP3457312B2 (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
ES2163410T3 (es) Derivados de benzodiazepina.
ES2032749T3 (es) Acidos oxoftalazinil-aceticos heterociclicos.
ATE46157T1 (de) Benzo(b>thiophen und benzo(b>furancarboxamidderivate, ihre verfahren zur herstellung und sie enthaltende arzneimittel.
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
NL971014I1 (nl) Heterocyclische verbindingen.
AR241161A2 (es) "procedimiento para la preparacion de derivados n-aminoalquilen sustituidos de la glutarimida"
BRPI0506817A (pt) inibidores seletivos de quinase
DE69132450D1 (de) Serotonin 5HT1A und 5HT1D Agonisten
DK0491664T3 (da) Indolderivater som serotonin-antagonister
ATE224T1 (de) 1,2-dihydro-chinolin-2-on-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel.
ES2062706T3 (es) Nuevos derivados de amino-metil-piperidina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ATE137238T1 (de) Beta-lactamantibiotika, verfahren zur herstellung und ihre verwendung als und in arzneimitteln
ATE137805T1 (de) Verfahren zur erhöhung von chemilumineszenz
ES2071325T3 (es) Derivados de 4-alquilimidazol.
ES2055115T3 (es) Derivados de fenil-amidina y fenil-guanidina sustituidos en posicion orto y agentes antidiabeticos y hipoglicemicos que los contienen.
DK691287A (da) 5-floururacilderivater
BR9801448B1 (pt) compostos heterocÍclicos, processo para sua preparaÇço e composiÇÕes farmacÊuticas contendo os mesmos.
AR241502A1 (es) Benzoil-ureas de accion insecticida. preparacion de las mismas. nueva amina aromatica para la preparacion de las benzoil-ureas y preparacion de la misma.
ATE96152T1 (de) 2-methylthiomethyl-dihydropyridine, verfahren zur herstellung und pharmazeutische zusammenstellungen, die sie enthalten.
AR021970A1 (es) Inhibidores de proteasas
ATE74496T1 (de) Aus guanidin- und ethanamidinessigsaeuren abgeleitete suessstoffe, ihre verwendung und diese suessstoffe enthaltende zusammensetzungen.
EP0349274A3 (en) Photographic dot enhancing compositions and methods for their use
BG60248B1 (bg) Метод за получаване на производни на феноксиетиламина
DK0580503T3 (da) Aminoalkylchromoner, fremgangsmåde til fremstilling heraf samt midler indeholdende disse
ES2055123T3 (es) Nuevos derivados de la fenotiazina, su preparacion y las composiciones que les contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 652871

Country of ref document: ES